Adjuvant Whole Brain Radiotherapy: Strong Emotions Decide But Rational Studies Are Needed

Paul D. Brown, Anthony L. Asher, Elana Farace

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Brain metastases are common in cancer patients and cause considerable morbidity and mortality. For patients with limited disease and good performance status, treatment typically involves a combination of focal measures (e.g., surgical resection or radiosurgery) for the radiographically apparent disease, followed by adjuvant whole brain radiotherapy (WBRT) to treat subclinical disease. Because of concerns regarding the toxicity of WBRT, especially neurocognitive deterioration, many have advocated withholding adjuvant WBRT. Recently published studies have shed more light on the efficacy of adjuvant WBRT and the neurocognitive effects of WBRT. However, the inclusion of neurocognitive and quality-of-life data in clinical trials are still required to better define the role of adjuvant WBRT. Currently, two Phase III trials are underway, one in Europe and one in North America, that will determine the effect of adjuvant WBRT on patients' quality of life, neurocognitive function, and survival.

Original languageEnglish (US)
Pages (from-to)1305-1309
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume70
Issue number5
DOIs
StatePublished - Apr 1 2008

Fingerprint

emotions
brain
radiation therapy
Emotions
Radiotherapy
Brain
Quality of Life
Radiosurgery
mortality
metastasis
North America
deterioration
toxicity
cancer
Clinical Trials
inclusions
Neoplasm Metastasis
Morbidity
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{0a29e413ae834529bb5390ceac2f4354,
title = "Adjuvant Whole Brain Radiotherapy: Strong Emotions Decide But Rational Studies Are Needed",
abstract = "Brain metastases are common in cancer patients and cause considerable morbidity and mortality. For patients with limited disease and good performance status, treatment typically involves a combination of focal measures (e.g., surgical resection or radiosurgery) for the radiographically apparent disease, followed by adjuvant whole brain radiotherapy (WBRT) to treat subclinical disease. Because of concerns regarding the toxicity of WBRT, especially neurocognitive deterioration, many have advocated withholding adjuvant WBRT. Recently published studies have shed more light on the efficacy of adjuvant WBRT and the neurocognitive effects of WBRT. However, the inclusion of neurocognitive and quality-of-life data in clinical trials are still required to better define the role of adjuvant WBRT. Currently, two Phase III trials are underway, one in Europe and one in North America, that will determine the effect of adjuvant WBRT on patients' quality of life, neurocognitive function, and survival.",
author = "Brown, {Paul D.} and Asher, {Anthony L.} and Elana Farace",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2007.11.047",
language = "English (US)",
volume = "70",
pages = "1305--1309",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

Adjuvant Whole Brain Radiotherapy : Strong Emotions Decide But Rational Studies Are Needed. / Brown, Paul D.; Asher, Anthony L.; Farace, Elana.

In: International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 5, 01.04.2008, p. 1305-1309.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant Whole Brain Radiotherapy

T2 - Strong Emotions Decide But Rational Studies Are Needed

AU - Brown, Paul D.

AU - Asher, Anthony L.

AU - Farace, Elana

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Brain metastases are common in cancer patients and cause considerable morbidity and mortality. For patients with limited disease and good performance status, treatment typically involves a combination of focal measures (e.g., surgical resection or radiosurgery) for the radiographically apparent disease, followed by adjuvant whole brain radiotherapy (WBRT) to treat subclinical disease. Because of concerns regarding the toxicity of WBRT, especially neurocognitive deterioration, many have advocated withholding adjuvant WBRT. Recently published studies have shed more light on the efficacy of adjuvant WBRT and the neurocognitive effects of WBRT. However, the inclusion of neurocognitive and quality-of-life data in clinical trials are still required to better define the role of adjuvant WBRT. Currently, two Phase III trials are underway, one in Europe and one in North America, that will determine the effect of adjuvant WBRT on patients' quality of life, neurocognitive function, and survival.

AB - Brain metastases are common in cancer patients and cause considerable morbidity and mortality. For patients with limited disease and good performance status, treatment typically involves a combination of focal measures (e.g., surgical resection or radiosurgery) for the radiographically apparent disease, followed by adjuvant whole brain radiotherapy (WBRT) to treat subclinical disease. Because of concerns regarding the toxicity of WBRT, especially neurocognitive deterioration, many have advocated withholding adjuvant WBRT. Recently published studies have shed more light on the efficacy of adjuvant WBRT and the neurocognitive effects of WBRT. However, the inclusion of neurocognitive and quality-of-life data in clinical trials are still required to better define the role of adjuvant WBRT. Currently, two Phase III trials are underway, one in Europe and one in North America, that will determine the effect of adjuvant WBRT on patients' quality of life, neurocognitive function, and survival.

UR - http://www.scopus.com/inward/record.url?scp=40949097767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949097767&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.11.047

DO - 10.1016/j.ijrobp.2007.11.047

M3 - Article

C2 - 18234426

AN - SCOPUS:40949097767

VL - 70

SP - 1305

EP - 1309

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -